FLOT alone

Phase 2Small molecule

AstraZeneca

FLOT alone is one of 93 small molecule programs targeting Gastric Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric AdenocarcinomaActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Gastric AdenocarcinomaPhase 1

Active, not recruiting

Esophageal AdenocarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Phase 3

11 2

HX008

BBinhui Biopharmaceutical Co., Ltd.

Phase 3

1 3

FLOT alone

AstraZeneca

Phase 2

1 4

Gemzar

Johnson & Johnson

Preclinical

—5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Glutamine

Sanofi

Preclinical

1 9

Induction Phase1

Genmab

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Gastric Adenocarcinoma

NCT07059299

Phase 3Active, not recruiting

Gastroesophageal Junction Cancer

NCT04592913

Q3 2028

Phase 2Recruiting

Gastroesophageal Adenocarcinoma

NCT07069712

Clinical

Trials by Indication[1]

Completed·RRuijin Hospital·Phase 2·NCT03636893·74 enrolled

Gastroesophageal Junction Cancer1 trial

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04592913·957 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07069712·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for FLOT alone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FLOT alone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FLOT alone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

FLOT alone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Gastric1 trial

Gastric Adenocarcinoma1 trial

Gastric Cancer1 trial

Gastroesophageal Junction Cancer1 trial

Gastroesophageal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News